Press releases

• May 6, 2021 - Regulatory press releaseReport from annual general meeting in BioArctic AB (publ)
• April 21, 2021 - Regulatory press releaseInterim Report for the period January – March 2021
• April 20, 2021 - Other press releaseLecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy

Archive

Calendar

• June 9, 2021Interim report January – June 2021
• October 21, 2021Interim report January – September 2021
• February 3, 2022Full Year Report 2021

Read more

Interim Report January - March 2021

BioArctic published the company’s Interim Report for the period January – March 2021 on Wednesday, April 21, 2021, at 08:00 a.m. CEST.

• Report
• Presentation
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more